Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost for Brain Metastases from Breast Cancers

Overview

Journal PeerJ

Specialties Biology
Environmental Health
General Medicine

Date 2024 Jul 16

PMID 39011372

Authors

Hongyan Zhang

Qiuji Wu

Li Li

Linwei Wang

Yahua Zhong

Affiliations

Soon will be listed here.

Abstract

Background: The effect of whole-brain radiation therapy (WBRT) plus simultaneous integrated boost (SIB) in brain metastasis from breast cancers has not been demonstrated.

Method: In this single-center retrospective study, we reviewed consecutive breast cancer patients who developed brain metastasis and were treated with hypofractionated radiation therapy plus WBRT using intensity-modulated radiation therapy (IMRT)-SIB approaches. We analyzed clinical outcomes, prognostic factors and patterns of treatment failure.

Result: A total of 27 patients were eligible for analysis. Four (14.8%) patients achieved clinical complete response and 14 (51.9%) had partial response of brain lesions. The other nine patients were not evaluated for brain tumor response. The median brain progression-free survival was 8.60 (95% CI [6.43-13.33]) months and the median overall survival was 16.8 (95% CI [13.3-27.7]) months. Three patients had in-field failure, five had out-field failure and two had in-field and out-field failure.

Conclusion: WBRT plus SIB led to improved tumor control and clinical outcome in breast cancer patients with brain metastasis.

Citing Articles

Metastatic brain tumors: from development to cutting-edge treatment.

Tanzhu G, Chen L, Ning J, Xue W, Wang C, Xiao G MedComm (2020). 2024; 6(1):e70020.

PMID: 39712454 PMC: 11661909. DOI: 10.1002/mco2.70020.

References

Halasz L, Uno H, Hughes M, DAmico T, Dexter E, Edge S . Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. Cancer. 2016; 122(13):2091-100. PMC: 4911286. DOI: 10.1002/cncr.30009. View

Qing D, Zhao B, Zhou Y, Zhu H, Ma D . Whole-brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non-small cell lung cancer: A single-institution study. Cancer Med. 2019; 9(1):238-246. PMC: 6943150. DOI: 10.1002/cam4.2696. View

Lin B, Huang D, Du H, Fan J, Zhang Y, Feng G . Whole-Brain Radiation Therapy With Simultaneous Integrated Boost Versus Whole-Brain Radiation Therapy Plus Stereotactic Radiosurgery for the Treatment of Brain Metastasis From Lung Cancer. Front Oncol. 2021; 11:631422. PMC: 7973358. DOI: 10.3389/fonc.2021.631422. View

Andrews D, Scott C, Sperduto P, Flanders A, Gaspar L, Schell M . Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363(9422):1665-72. DOI: 10.1016/S0140-6736(04)16250-8. View

Lombardi G, Di Stefano A, Farina P, Zagonel V, Tabouret E . Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat Rev. 2014; 40(8):951-9. DOI: 10.1016/j.ctrv.2014.05.007. View

Christodoulou C, Kalogera-Fountzila A, Karavasilis V, Kouvatseas G, Papandreou C, Samantas E . Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG). J Neurooncol. 2017; 134(2):443-451. DOI: 10.1007/s11060-017-2548-z. View

Lin N, Amiri-Kordestani L, Palmieri D, Liewehr D, Steeg P . CNS metastases in breast cancer: old challenge, new frontiers. Clin Cancer Res. 2013; 19(23):6404-18. PMC: 7580496. DOI: 10.1158/1078-0432.CCR-13-0790. View

Possanzini M, Greco C . Stereotactic radiotherapy in metastatic breast cancer. Breast. 2018; 41:57-66. DOI: 10.1016/j.breast.2018.06.011. View

Bauman G, Yartsev S, Roberge D, MacRae R, Roa W, Panet-Raymond V . Assessment of function and quality of life in a phase II multi-institutional clinical trial of fractionated simultaneous in-field boost radiotherapy for patients with 1-3 metastases. J Neurooncol. 2016; 128(3):431-6. DOI: 10.1007/s11060-016-2128-7. View

10.

Mix M, Elmarzouky R, OConnor T, Plunkett R, Prasad D . Clinical outcomes in patients with brain metastases from breast cancer treated with single-session radiosurgery or whole brain radiotherapy. J Neurosurg. 2016; 125(Suppl 1):26-30. DOI: 10.3171/2016.7.GKS161541. View

11.

Westover K, Mendel J, Dan T, Kumar K, Gao A, Pulipparacharuv S . Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer. Neuro Oncol. 2020; 22(12):1831-1839. PMC: 7746928. DOI: 10.1093/neuonc/noaa092. View

12.

Yang J, Zhan W, Zhang H, Song T, Jia Y, Xu H . Intensity-modulated radiation therapy for patients with 1 to 3 brain metastases in recursive partitioning analysis class 3. Medicine (Baltimore). 2017; 96(40):e7715. PMC: 5737988. DOI: 10.1097/MD.0000000000007715. View

13.

Lorger M, Felding-Habermann B . Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol. 2010; 176(6):2958-71. PMC: 2877856. DOI: 10.2353/ajpath.2010.090838. View

14.

Pelletier E, Shim B, Goodman S, Amonkar M . Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat. 2007; 108(2):297-305. DOI: 10.1007/s10549-007-9601-0. View

15.

Jeene P, de Vries K, van Nes J, Kwakman J, Wester G, Rozema T . Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014. Acta Oncol. 2017; 57(5):637-643. DOI: 10.1080/0284186X.2017.1418534. View

16.

Castaneda C, Flores R, Rojas K, Castillo M, Dolores-Cerna K, Flores C . Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer. CNS Oncol. 2015; 4(3):137-45. PMC: 6088333. DOI: 10.2217/cns.15.5. View

17.

Buonomo O, Caredda E, Portarena I, Vanni G, Orlandi A, Bagni C . New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. PLoS One. 2017; 12(9):e0184680. PMC: 5602519. DOI: 10.1371/journal.pone.0184680. View

18.

Du T, Li X, Zhong W, Tian J, Zhao Y, Liu D . Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost. J Cancer Res Clin Oncol. 2020; 147(2):569-577. DOI: 10.1007/s00432-020-03359-8. View

19.

Popp I, Rau S, Hintz M, Schneider J, Bilger A, Fennell J . Hippocampus-avoidance whole-brain radiation therapy with a simultaneous integrated boost for multiple brain metastases. Cancer. 2020; 126(11):2694-2703. DOI: 10.1002/cncr.32787. View

20.

Chia B, Leong J, Ong A, Lim C, Poon S, Chua M . Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol. BMC Cancer. 2020; 20(1):1045. PMC: 7602352. DOI: 10.1186/s12885-020-07565-y. View